Caption Management’s Intellia Therapeutics NTLA Stock Holding History

Caption Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.33M	Sell	78,600 -26,400	-25%	-$370K	0.01%	1033
2026 Q1	$1.35M	Buy	105,000 +60,000	+133%	+$764K	0.01%	932
2025 Q4	$405K	Sell	45,000 -75,000	-63%	-$1.03M	﹤0.01%	1274
2025 Q3	$2.07M	Buy	120,000 +85,000	+243%	+$1.05M	0.02%	833
2025 Q2	$328K	Hold	35,000	–	–	﹤0.01%	1196
2025 Q1	$249K	Sell	35,000 -25,000	-42%	-$253K	﹤0.01%	1232
2024 Q4	$700K	Sell	60,000 -32,100	-35%	-$501K	0.01%	1000
2024 Q3	$1.89M	Buy	92,100 +55,900	+154%	+$1.29M	0.03%	580
2024 Q2	$810K	Hold	36,200	–	–	0.01%	712
2024 Q1	$996K	Sell	36,200 -1,300	-3%	-$36.1K	0.02%	734
2023 Q4	$1.14M	Sell	37,500 -7,500	-17%	-$216K	0.02%	773
2023 Q3	$1.42M	Sell	45,000 -15,000	-25%	-$582K	0.02%	672
2023 Q2	$2.45M	Hold	60,000	–	–	0.04%	447
2023 Q1	$2.24M	Buy	60,000 +35,000	+140%	+$1.37M	0.04%	420
2022 Q4	$872K	Sell	25,000 -45,000	-64%	-$2.14M	0.01%	794
2022 Q3	$3.92M	Hold	70,000	–	–	0.05%	419
2022 Q2	$3.62M	Sell	70,000 -42,500	-38%	-$2.16M	0.05%	474
2022 Q1	$8.17M	Buy	112,500 +75,200	+202%	+$6.37M	0.1%	281
2021 Q4	$4.41M	Sell	37,300 -80,200	-68%	-$10M	0.05%	495
2021 Q3	$15.8M	Sell	117,500 -386,600	-77%	-$58.5M	0.18%	140
2021 Q2	$81.6M	Buy	504,100 +294,800	+141%	+$23M	1.07%	7
2021 Q1	$16.8M	Buy	209,300 +109,300	+109%	+$7.34M	0.36%	52
2020 Q4	$5.44M	Buy	+100,000	New	+$3.63M	0.12%	206

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Caption Management's NTLA Position: Q2 2026 in Review

Caption Management opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 84,700 shares worth $1.43M. The stake represents 0.01% of the portfolio and ranks #1009 among its holdings. This is a return to the name: Caption Management previously reported a position in NTLA as recently as Q4 2025.

Caption Management first reported a position in NTLA in Q1 2021 and has held it in 16 quarters since. The position peaked at $3.03M in Q1 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Caption Management held 84,700 shares of Intellia Therapeutics worth $1.43M as of Q2 2026.
Intellia Therapeutics was a new Caption Management position in Q2 2026.
Intellia Therapeutics made up 0.01% of Caption Management's portfolio in Q2 2026, its #1009 holding.
Caption Management first reported a position in Intellia Therapeutics in Q1 2021 and has held it in 16 quarters since.
Caption Management's Intellia Therapeutics position peaked at $3.03M in Q1 2021.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.